Loading...
Printed on 6/29/2026
For informational purposes only. This is not medical advice.
Warfarin is a commonly used anticoagulant that requires careful dose titration based on the International Normalized Ratio (INR). This tool provides evidence-based dose adjustment guidance based on the patient's current INR relative to their target INR range. It covers scenarios from sub-therapeutic to dangerously elevated INR levels with specific action recommendations.
Formula: Evidence-based INR-guided dose adjustment recommendations
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Input the patient's most recent INR result and their target therapeutic range. The most common target is 2.0–3.0 for atrial fibrillation, DVT/PE treatment, and bioprosthetic valves. Mechanical mitral valves or antiphospholipid syndrome typically require a higher target of 2.5–3.5. The target range determines whether the INR is subtherapeutic, therapeutic, or supratherapeutic.
Input the total weekly dose of warfarin in milligrams (sum all daily doses across the week). The calculator provides percentage adjustment guidance: if INR is subtherapeutic, increase weekly dose 10–20%; if supratherapeutic, decrease 10–20% or hold dose. Dose changes are made to the weekly total, not the daily dose, because warfarin is often taken as different doses on different days.
The output includes the suggested new weekly dose, the recommended next INR check interval (more frequent monitoring when outside range), and whether bridging anticoagulation or urgent reversal is indicated. For INR >5, bridging is generally not needed; focus is on dose reduction and recheck. For INR >8–10 or active bleeding, urgent reversal with 10 mg IV vitamin K plus 4-factor PCC is indicated.
Anticoagulation Pharmacists & Nurses
Systematic dose adjustment for patients enrolled in anticoagulation management services. Clinics use structured INR-to-dose algorithms to maintain time-in-therapeutic-range (TTR) above 65–70%, the threshold associated with optimal outcomes in AF and VTE patients.
Cardiologists & Internists
Warfarin remains a first-line option for stroke prevention in AF patients with mechanical heart valves, severe renal disease (eGFR <15), or where DOACs are not appropriate. INR target 2.0–3.0 reduces stroke risk by 64% compared to placebo.
Hospitalists & Hematologists
Warfarin is used for long-term DVT/PE anticoagulation after initial parenteral therapy. Target INR 2.0–3.0. Bridging with LMWH is required until INR is therapeutic for at least 24 hours on two consecutive measurements.
Cardiac Surgery & Cardiology Teams
Warfarin remains the only approved anticoagulant for mechanical prosthetic heart valves — DOACs are inferior in this setting. INR target depends on valve type and position: bileaflet aortic valves 2.0–3.0; mitral valves or older valve types 2.5–3.5.
Rheumatologists & Hematologists
High-risk antiphospholipid syndrome (triple positivity: LA, aCL, anti-β2GPI) requires warfarin with target INR 2.5–3.5. DOACs are inferior for APS-associated thrombosis per the TRAPS trial. Strict INR monitoring is essential given thrombotic recurrence risk.
INR 1.8 and INR 4.5 are both suboptimal — the former risks thromboembolism, the latter risks bleeding. Time-in-therapeutic-range (TTR) above 65–70% is the key quality metric. A patient with TTR <65% should be considered for DOAC transition if appropriate.
TTR is the strongest predictor of clinical outcomes on warfarin. Patients with TTR <65% have comparable or worse outcomes than patients on DOACs. TTR can be improved with more frequent monitoring, patient education, and consistent vitamin K intake.
Large changes in dietary vitamin K (green leafy vegetables: kale, spinach, Brussels sprouts) directly affect INR. Encourage consistent — not zero — vitamin K intake. Sudden dietary changes cause more INR instability than a consistently high intake.
Many antibiotics (fluoroquinolones, metronidazole, fluconazole, trimethoprim-sulfamethoxazole) significantly potentiate warfarin by inhibiting CYP2C9 or reducing gut bacteria that produce menaquinone (vitamin K2). Recheck INR 5–7 days after starting any antibiotic.
Amiodarone is one of the most potent warfarin potentiators — it inhibits CYP2C9 and CYP3A4. When starting amiodarone, reduce the warfarin dose by 30–50% empirically and monitor INR every 1–2 weeks until stable. The interaction persists for months after amiodarone discontinuation due to its long half-life.
For INR 5–8 without significant bleeding: hold warfarin for 1–2 days, consider low-dose vitamin K (1–2.5 mg orally), and recheck INR in 1–3 days. Oral vitamin K at this dose rapidly lowers INR without causing resistance to re-anticoagulation.
For INR >8–10 or any major bleeding: give vitamin K 10 mg IV slowly (over 20–30 minutes to avoid anaphylaxis-like reactions) plus 4-factor prothrombin complex concentrate (4F-PCC). Fresh frozen plasma is an alternative if PCC is unavailable. Recombinant factor VIIa is not routinely recommended.
For AF and VTE (excluding mechanical valves and APS), DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred: no INR monitoring, fewer drug-food interactions, better safety profiles in most populations. Warfarin remains superior only for mechanical heart valves and high-risk APS.
No DOAC is approved for mechanical prosthetic heart valves. The RE-ALIGN trial showed dabigatran had higher stroke and bleeding rates than warfarin in this population. All patients with mechanical valves must use warfarin — this is a hard contraindication to DOAC use.
Hold warfarin 5 days before elective surgery (INR target <1.5 for most procedures, <1.2 for neuraxial anesthesia). Bridging with LMWH heparin is required only for high-risk patients: mechanical mitral valve, recent VTE (<3 months), or AF with prior stroke/TIA. Most AF patients do NOT need bridging — it increases bleeding without reducing thromboembolism.
Warfarin therapy guidance from the Chest Antithrombotic Guidelines (Kearon et al., Chest 2016). TTR >65–70% associated with best outcomes in AF: Connolly et al. (Circulation 2008). Vitamin K1 (2.5–5 mg oral) for INR 5–10 shown effective by Crowther et al. (Ann Intern Med 2000). Mechanical valve anticoagulation guidelines: Nishimura et al. (JACC 2017). CHEST 2022 guidelines update on VTE management. Pharmacogenomics of warfarin (CYP2C9, VKORC1) improves initial dosing per FDA labeling update 2010.
The calculator provides dose adjustment guidance based on where the current INR falls relative to the target range. An INR within the target range (commonly 2.0–3.0 for most indications) indicates therapeutic anticoagulation, and the current dose should generally be maintained. An INR below the target suggests sub-therapeutic anticoagulation, meaning the patient is not adequately protected against clot formation and may need a dose increase.
An INR above the target range indicates excessive anticoagulation and increased bleeding risk. Mildly elevated INR (just above target) may require holding one dose and a small dose reduction. Significantly elevated INR (above 4.5–5.0) requires more aggressive intervention including holding warfarin and potentially administering vitamin K. An INR above 9 is a medical emergency requiring urgent management regardless of whether active bleeding is present.
Use this tool when managing patients on warfarin anticoagulation therapy to guide dose adjustments based on INR results. Warfarin requires regular INR monitoring — typically every 1–4 weeks for stable patients, and more frequently during dose titration, initiation, or when interacting medications are started or stopped.
Common indications for warfarin therapy include atrial fibrillation (target INR 2.0–3.0), deep vein thrombosis or pulmonary embolism (target INR 2.0–3.0), mechanical heart valves (target varies by valve type and position, typically 2.5–3.5 for mitral valves), and certain hypercoagulable states. The tool helps standardize dose adjustment decisions using evidence-based protocols.
This tool provides general dose adjustment guidance and does not replace individualized clinical judgment. Warfarin dosing is affected by numerous factors including diet (vitamin K intake from green leafy vegetables), concurrent medications (antibiotics, antifungals, amiodarone, NSAIDs, and many others), alcohol consumption, liver function, thyroid status, and genetic variants in CYP2C9 and VKORC1 that affect warfarin metabolism and sensitivity.
Dose adjustments should generally be made in increments of 5–15% of the total weekly dose, and the effect of a dose change takes 3–5 days to be reflected in the INR due to warfarin's long half-life (36–42 hours) and the time needed for clotting factor turnover. Rechecking INR too soon after a dose change may lead to inappropriate further adjustments.
The tool does not account for the clinical context of INR elevation — a patient with a mildly elevated INR who is otherwise well is managed differently from one who is actively bleeding. Patients with signs of active bleeding at any INR level require emergent evaluation and may need reversal agents (vitamin K, fresh frozen plasma, or prothrombin complex concentrate) regardless of the dose adjustment guidance.
For related assessments, see HAS-BLED Score, CHA₂DS₂-VASc Score and Wells Score (DVT).
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate the HAS-BLED score to assess bleeding risk in patients on anticoagulation therapy. Balance stroke prevention against bleeding risk.
OpenCardiologyCalculate the CHA₂DS₂-VASc score to estimate stroke risk in patients with atrial fibrillation and guide anticoagulation therapy decisions.
OpenEmergencyCalculate Wells DVT pretest probability in seconds. Score 10 clinical criteria for low, moderate, or high DVT risk — with D-dimer and ultrasound next steps.
Open